Millipede 088 Aspiration Catheter
Acute Ischemic Stroke (Large Vessel Occlusion)
Pivotal Trial (IDE)Active
Key Facts
Indication
Acute Ischemic Stroke (Large Vessel Occlusion)
Phase
Pivotal Trial (IDE)
Status
Active
Company
About Perfuze
Perfuze is a private, clinical-stage medical device company targeting the significant unmet need in acute ischemic stroke treatment. Its core technology is the Millipede 088, a next-generation 'superbore' aspiration catheter engineered to achieve higher rates of complete clot ingestion and first-pass reperfusion compared to current stent retriever and small-bore aspiration methods. With its pivotal MARRS IDE trial data presented in 2025, the company is advancing toward regulatory approval and commercialization, aiming to improve patient outcomes in a large and growing global market.
View full company profileTherapeutic Areas
Other Acute Ischemic Stroke (Large Vessel Occlusion) Drugs
| Drug | Company | Phase |
|---|---|---|
| FreeClimb Catheter Systems (54, 70, 88) | Route 92 Medical | Approved |
| HiPoint Reperfusion System | Route 92 Medical | Pivotal Trial |
| Lead Ischemic Stroke Program | RapidPulse | Pivotal |
| NeVa / NeVa VS | Vesalio | Commercial |